Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells

Toxicology in Vitro

Volumn 21, Issue 8, 2007, Pages 1581-1591

  Westerink, Walter M A ^a   Schoonen, Willem G E J ^a  

^a NV Organon ^*  (Netherlands)

Author keywords

Cytochrome P450; Cytotoxicity; Hepatocytes; HepG2; Induction studies; Phase I metabolism

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; MESSENGER RNA; PREGNANE X RECEPTOR;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; ENZYME ANALYSIS; ENZYME INDUCTION; ENZYME REGULATION; HUMAN; HUMAN CELL; LIVER CELL; POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; CELL LINE; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER; TRANSCRIPTION FACTORS;

RATTUS;

EID: 36148955117     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2007.05.014     Document Type: Article

References (63)

1. Adachi J., Mori Y., Matsui S., Takigami H., Fujino J., Kitagawa H., Miller III C.A., Kato T., Saeki K., and Matsuda T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 276 (2001) 31475-31478
2. Bao H., Vepakomma M., and Sarkar M.A. Benzo(a)pyrene exposure induces CYP1A1 activity and expression in human endometrial cells. J. Steroid Biochem. Mol. Biol. 81 (2002) 37-45
3. Berson A., Wolf C., Chachaty C., Fisch C., Fau D., Eugene D., Loeper J., Gauthier J.C., Beaune P., and Pompon D. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J. Pharmacol. Exp. Ther. 265 (1993) 366-372
4. Bock K.W., and Kohle C. Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucuronide transporters. Drug Metab. Rev. 36 (2004) 595-615
5. Caldwell G.W., Ritchie D.M., Masucci J.A., Hageman W., and Yan Z. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr. Top. Med. Chem. 1 (2001) 353-366
6. Cali J.J., Ma D., Sobol M., Simpson D.J., Frackman S., Good T.D., Daily W.J., and Liu D. Luminogenic cytochrome P450 assays. Expert. Opin. Drug Metab. Toxicol. 2 (2006) 629-645
7. Carroccio A., Wu D., and Cederbaum A.I. Ethanol increases content and activity of human cytochrome P4502E1 in a transduced HepG2 cell line. Biochem. Biophys. Res. Commun. 203 (1994) 727-733
8. Catania J.R., McGarrigle B.P., Rittenhouse-Olson K., and Olson J.R. Induction of CYP2B and CYP2E1 in precision-cut rat liver slices cultured in defined medium. Toxicol. in Vitro 21 (2007) 109-115
9. Chen Y., Ferguson S.S., Negishi M., and Goldstein J.A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther. 308 (2004) 495-501
10. Coe K.J., Nelson S.D., Ulrich R.G., He Y., Dai X., Cheng O., Caguyong M., Roberts C.J., and Slatter J.G. Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers. Drug Metab. Dispos. 34 (2006) 1266-1275
11. Conney A.H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes Memorial Lecture. Cancer Res. 42 (1982) 4875-4917
12. Corcos L., Marc N., Wein S., Fautrel A., Guillouzo A., and Pineau T. Phenobarbital induces cytochrome P4501A2 hnRNA, mRNA and protein in the liver of C57BL/6J wild type and aryl hydrocarbon receptor knock-out mice. FEBS Lett. 425 (1998) 293-297
13. Faucette S.R., Hawke R.L., LeCluyse E.L., Shord S.S., Yan B., Laethem R.M., and Lindley C.M. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28 (2000) 1222-1230
14. Faucette S.R., Wang H., Hamilton G.A., Jolley S.L., Gilbert D., Lindley C., Yan B., Negishi M., and LeCluyse E.L. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab. Dispos. 32 (2004) 348-358
15. Faucette S.R., Sueyoshi T., Smith C.M., Negishi M., LeCluyse E.L., and Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317 (2006) 1200-1209
16. Ferguson S.S., Chen Y., LeCluyse E.L., Negishi M., and Goldstein J.A. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol. Pharmacol. 68 (2005) 747-757
17. Fradette C., Yamaguchi N., and Du S.P. 5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide. Br. J. Pharmacol. 141 (2004) 407-414
18. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M., Carrere N., and Maurel P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29 (2001) 242-251
19. Gervot L., Rochat B., Gautier J.C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., Beaune P., and de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9 (1999) 295-306
20. Goldstein J.A., and de Morais S.M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4 (1994) 285-299
21. Gross-Steinmeyer K., Stapleton P.L., Tracy J.H., Bammler T.K., Lehman T., Strom S.C., and Eaton D.L. Influence of Matrigel-overlay on constitutive and inducible expression of nine genes encoding drug-metabolizing enzymes in primary human hepatocytes. Xenobiotica 35 (2005) 419-438
22. Hecht S.S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11 (1998) 559-603
23. Hewitt N.J., and Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34 (2004) 243-256
24. Huang W.Y., Chatterjee N., Chanock S., Dean M., Yeager M., Schoen R.E., Hou L.F., Berndt S.I., Yadavalli S., Johnson C.C., and Hayes R.B. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 152-157
25. Huang Z., Roy P., and Waxman D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59 (2000) 961-972
26. Jover R., Bort R., Gomez-Lechon M.J., and Castell J.V. Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett. 431 (1998) 227-230
27. Knasmuller S., Mersch-Sundermann V., Kevekordes S., Darroudi F., Huber W.W., Hoelzl C., Bichler J., and Majer B.J. Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology 198 (2004) 315-328
28. Knasmuller S., Schwab C.E., Land S.J., Wang C.Y., Sanyal R., Kundi M., Parzefall W., and Darroudi F. Genotoxic effects of heterocyclic aromatic amines in human derived hepatoma (HepG2) cells. Mutagenesis 14 (1999) 533-540
29. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715
30. Lewis D.F., Ioannides C., and Parke D.V. Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen. Environ. Health Perspect. 106 (1998) 633-641
31. Li A.P., Reith M.K., Rasmussen A., Gorski J.C., Hall S.D., Xu L., Kaminski D.L., and Cheng L.K. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 107 (1997) 17-30
32. Madan A., Graham R.A., Carroll K.M., Mudra D.R., Burton L.A., Krueger L.A., Downey A.D., Czerwinski M., Forster J., Ribadeneira M.D., Gan L.S., LeCluyse E.L., Zech K., Robertson Jr. P., Koch P., Antonian L., Wagner G., Yu L., and Parkinson A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 31 (2003) 421-431
33. Maglich J.M., Parks D.J., Moore L.B., Collins J.L., Goodwin B., Billin A.N., Stoltz C.A., Kliewer S.A., Lambert M.H., Willson T.M., and Moore J.T. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 278 (2003) 17277-17283
34. Maglich J.M., Stoltz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., and Kliewer S.A. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 62 (2002) 638-646
35. Mankowski D.C., and Ekins S. Prediction of human drug metabolizing enzyme induction. Curr. Drug Metab. 4 (2003) 381-391
36. Moore J.T., Moore L.B., Maglich J.M., and Kliewer S.A. Functional and structural comparison of PXR and CAR. Biochim. Biophys. Acta 1619 (2003) 235-238
37. Morrow C.S., Diah S., Smitherman P.K., Schneider E., and Townsend A.J. Multidrug resistance protein and glutathione S-transferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity. Carcinogenesis 19 (1998) 109-115
38. Nadin L., and Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem. Pharmacol. 58 (1999) 1201-1208
39. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., and Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80 (2006) 580-604
40. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299 (2001) 849-857
41. Raucy J.L., Lasker J., Ozaki K., and Zoleta V. Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol. Sci. 79 (2004) 233-241
42. Rodriguez-Antona C., Donato M.T., Boobis A., Edwards R.J., Watts P.S., Castell J.V., and Gomez-Lechon M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32 (2002) 505-520
43. Rooney P.H., Telfer C., McFadyen M.C., Melvin W.T., and Murray G.I. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr. Cancer Drug Targ. 4 (2004) 257-265
44. Runge D., Kohler C., Kostrubsky V.E., Jager D., Lehmann T., Runge D.M., May U., Stolz D.B., Strom S.C., Fleig W.E., and Michalopoulos G.K. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem. Biophys. Res. Commun. 273 (2000) 333-341
45. Schoonen W.G., de Roos J.A., Westerink W.M., and Debiton E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol. in Vitro 19 (2005) 491-503
46. Schoonen W.G., Westerink W.M., de Roos J.A., and Debiton E. Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol. in Vitro 19 (2005) 505-516
47. Shenoy S.D., Spencer T.A., Mercer-Haines N.A., Alipour M., Gargano M.D., Runge-Morris M., and Kocarek T.A. CYP3A induction by liver x receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor. Drug Metab. Dispos. 32 (2004) 66-71
48. Shimada T., Iwasaki M., Martin M.V., and Guengerich F.P. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res. 49 (1989) 3218-3228
49. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., and Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56 (1996) 2979-2984
50. Silver G., Reid L.M., and Krauter K.S. Dexamethasone-mediated regulation of 3-methylcholanthrene-induced cytochrome P-450d mRNA accumulation in primary rat hepatocyte cultures. J. Biol. Chem. 265 (1990) 3134-3138
51. Sugihara K., Kitamura S., Yamada T., Okayama T., Ohta S., Yamashita K., Yasuda M., Fujii-Kuriyama Y., Saeki K., Matsui S., and Matsuda T. Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo. Biochem. Biophys. Res. Commun. 318 (2004) 571-578
52. Townsend A.J., Kabler S.L., Doehmer J., and Morrow C.S. Modeling the metabolic competency of glutathione S-transferases using genetically modified cell lines. Toxicology 181-182 (2002) 265-269
53. Vignati L., Turlizzi E., Monaci S., Grossi P., Kanter R., and Monshouwer M. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216 (2005) 154-167
54. Walubo A., Smith P., and Folb P.I. The role of oxygen free radicals in isoniazid-induced hepatotoxicity. Methods Find. Exp. Clin. Pharmacol. 20 (1998) 649-655
55. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369 (1999) 11-23
56. Wei P., Zhang J., Dowhan D.H., Han Y., and Moore D.D. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogen. J. 2 (2002) 117-126
57. Westerink, W.M., Schoonen, G.E.J., accepted for publication. Phase II enzyme levels in HepG2 cells and cryopreserved human primary human hepatocytes and their induction in HepG2 cells. Toxicol. in Vitro.
58. Whitlock Jr. J.P. Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 103-125
59. Wilkening S., Stahl F., and Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 31 (2003) 1035-1042
60. Wu D., Ramin S.A., and Cederbaum A.I. Effect of pyridine on the expression of cytochrome P450 isozymes in primary rat hepatocyte culture. Mol. Cell Biochem. 173 (1997) 103-111
61. Xie W., Yeuh M.F., Radominska-Pandya A., Saini S.P., Negishi Y., Bottroff B.S., Cabrera G.Y., Tukey R.H., and Evans R.M. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc. Natl. Acad. Sci. USA 100 (2003) 4150-4155
62. Yamamoto Y., Yamazaki H., Ikeda T., Watanabe T., Iwabuchi H., Nakajima M., and Yokoi T. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 30 (2002) 155-160
63. Yueh M.F., Kawahara M., and Raucy J. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol. in Vitro 19 (2005) 275-287